“Moreover, the introduction of non-calcium-based phosphate binders (sevelamer and lanthanum carbonate ) and cinacalcet (an allosteric activator of the calcium receptor that reduces PTH and the serum calciumxphosphate product) may reduce the risk of hypercalcemia with vitamin D therapy.”